Skip to main content
Journal cover image

Comparison of vessel dilator and long-acting natriuretic peptide in the treatment of congestive heart failure.

Publication ,  Journal Article
Vesely, DL; Dietz, JR; Parks, JR; Antwi, EA; Overton, RM; McCormick, MT; Cintron, G; Schocken, DD
Published in: Am Heart J
October 1999

BACKGROUND: Long-acting natriuretic peptide (LANP; proANF 1-30) and vessel dilator (proANF 31-67) enhance sodium and water excretion in healthy human beings. The current investigation was designed to compare the beneficial effects of LANP and vessel dilator in persons with congestive heart failure (CHF). METHODS AND RESULTS: LANP and vessel dilator (100 ng/kg body weight/min, respectively) were given intravenously for 60 minutes to subjects with New York Heart Association class III CHF (n = 17) while their urine volume and sodium and potassium excretion were monitored. Vessel dilator increased urine flow more than 5-fold, which was still increased (P <.001) 3 hours after stopping its infusion. Vessel dilator enhanced sodium excretion 3-fold in subjects with CHF (P <.01), which was still significantly (P <.01) elevated 3 hours after infusion. The effects of LANP were diminished, with urine flow only increasing 2-fold (P <.05). The fractional excretion of sodium increased maximally 6-fold secondary to vessel dilator and 3-fold with LANP. The CHF control patients had no changes in the above parameters. Part of the diminished response to LANP was found to be caused by its rapid decrease in the circulation of individuals with CHF. CONCLUSIONS: These results indicate that vessel dilator has significant beneficial diuretic and natriuretic properties, which are not diminished, whereas the effects of LANP are diminished in human beings with CHF compared with healthy individuals.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am Heart J

DOI

ISSN

0002-8703

Publication Date

October 1999

Volume

138

Issue

4 Pt 1

Start / End Page

625 / 632

Location

United States

Related Subject Headings

  • Time Factors
  • Protein Precursors
  • Peptide Fragments
  • Osmolar Concentration
  • Natriuresis
  • Middle Aged
  • Male
  • Infusions, Intravenous
  • Humans
  • Heart Failure
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vesely, D. L., Dietz, J. R., Parks, J. R., Antwi, E. A., Overton, R. M., McCormick, M. T., … Schocken, D. D. (1999). Comparison of vessel dilator and long-acting natriuretic peptide in the treatment of congestive heart failure. Am Heart J, 138(4 Pt 1), 625–632. https://doi.org/10.1016/s0002-8703(99)70175-4
Vesely, D. L., J. R. Dietz, J. R. Parks, E. A. Antwi, R. M. Overton, M. T. McCormick, G. Cintron, and D. D. Schocken. “Comparison of vessel dilator and long-acting natriuretic peptide in the treatment of congestive heart failure.Am Heart J 138, no. 4 Pt 1 (October 1999): 625–32. https://doi.org/10.1016/s0002-8703(99)70175-4.
Vesely DL, Dietz JR, Parks JR, Antwi EA, Overton RM, McCormick MT, et al. Comparison of vessel dilator and long-acting natriuretic peptide in the treatment of congestive heart failure. Am Heart J. 1999 Oct;138(4 Pt 1):625–32.
Vesely, D. L., et al. “Comparison of vessel dilator and long-acting natriuretic peptide in the treatment of congestive heart failure.Am Heart J, vol. 138, no. 4 Pt 1, Oct. 1999, pp. 625–32. Pubmed, doi:10.1016/s0002-8703(99)70175-4.
Vesely DL, Dietz JR, Parks JR, Antwi EA, Overton RM, McCormick MT, Cintron G, Schocken DD. Comparison of vessel dilator and long-acting natriuretic peptide in the treatment of congestive heart failure. Am Heart J. 1999 Oct;138(4 Pt 1):625–632.
Journal cover image

Published In

Am Heart J

DOI

ISSN

0002-8703

Publication Date

October 1999

Volume

138

Issue

4 Pt 1

Start / End Page

625 / 632

Location

United States

Related Subject Headings

  • Time Factors
  • Protein Precursors
  • Peptide Fragments
  • Osmolar Concentration
  • Natriuresis
  • Middle Aged
  • Male
  • Infusions, Intravenous
  • Humans
  • Heart Failure